GlassScriptPhysician profile
Timothy D Cassidy
NPI 1750948287
$12,435.03
in general payments reported to CMS, 2019-2025
29 companies · $2,778 in 2025
The $2,778 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $2,650 · 2023: $3,943 · 2024: $2,802 · 2025: $2,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,108 · Education: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,107.71 |
| Education | $414.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,280.37 | 2021-2025 | |
| Amgen INC. | $1,756.54 | 2022-2025 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $1,707.30 | 2022-2025 | Tremfya, Simponi Aria, Xarelto |
| Lilly USA, LLC | $852.01 | 2022-2025 | Taltz |
| Glaxosmithkline, LLC. | $714.46 | 2022-2025 | Benlysta |
| Ucb, INC. | $681.70 | 2022-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $521.96 | 2022-2025 | |
| Horizon Therapeutics Plc | $450.60 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $418.76 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $393.04 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $194.00 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $180.24 | 2022-2025 | Actemra |
| Organon LLC | $180.09 | 2022-2024 | Hadlima, Renflexis |
| E.R. Squibb & Sons, L.L.C. | $180.00 | 2022-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.12 | 2022-2024 | Ofev, Cyltezo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $116.31 | 2023-2025 | Hyrimoz, Jubbonti |
| Alexion Pharmaceuticals, INC. | $102.46 | 2023-2024 | Strensiq, Ultomiris |
| Fresenius Kabi USA, LLC | $81.56 | 2023-2024 | Idacio |
| Astrazeneca Pharmaceuticals LP | $81.31 | 2022-2024 | Saphnelo |
| Actelion Pharmaceuticals US, INC. | $76.29 | 2022-2025 | Uptravi, Opsumit |
| Sobi, INC | $59.46 | 2022-2024 | |
| Fidia Pharma USA INC. | $53.74 | 2022-2025 | Hymovis, Triluron |
| Radius Health, INC. | $47.80 | 2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $32.38 | 2023 | Purified Cortrophin Gel |
| Genzyme Corporation | $29.33 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $25.47 | 2025 | |
| Depuy Synthes Sales INC. | $22.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.87 | 2024 | Truxima |
| Ibsa Pharma INC. | $16.86 | 2024 | Tirosint, Flector, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cassidy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.